Transcriptomics

Dataset Information

0

Microarray data of CACTg/Tg;APC580S mouse model exposed to 1, 2, and 5 mg/kg;bw/day of E171 via intragastric administration for 2, 7, 14, and 21 days.


ABSTRACT: Titanium dioxide (TiO2) is present in many different food products as food additive E171 and is currently scrutinized, due to its potential adverse effects, including the stimulation of tumor formation in the gastrointestinal tract. We developed a transgenic mouse model to examine the effects of E171 on colorectal cancer (CRC), using the Cre-LoxP system to create an Apc-gene-knockout model which spontaneously develops colorectal tumors. In phase I of this study, tumor formation was studied following the exposure to 5 mg/kgbw/day of E171 for 9 weeks. E171-exposure increased the number of transgenic mice with colorectal tumors as well as the average number and size of these tumors. Colorectal adenocarcinomas were accompanied by enhanced hyperplasia in epithelial cells and lymphatic nodules at the base of the polyps. In phase II, gene expression changes in the colon were analyzed after exposure to 1, 2, and 5 mg/kgbw/day of E171 for 2, 7, 14, and 21 days. Whole-genome mRNA analysis revealed the modulation of genes in pathways involved in the regulation of gene expression, cell cycle, post-translational modification, nuclear receptor signaling, and circadian rhythm. The processes associated with these genes might be involved in the enhanced tumor formation and suggest that E171 may contribute to tumor formation and progression by modulation of events related to inflammation, activation of immune responses, cell cycle, and cancer signaling.

ORGANISM(S): Mus musculus

PROVIDER: GSE186727 | GEO | 2022/04/12

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-01-24 | GSE92563 | GEO
2018-07-15 | GSE109520 | GEO
2019-11-22 | GSE110410 | GEO
| 2443066 | ecrin-mdr-crc
2013-12-31 | E-GEOD-47413 | biostudies-arrayexpress
2024-09-02 | BIOMD0000000863 | BioModels
2013-12-31 | GSE47413 | GEO
| 20119 | ecrin-mdr-crc
2023-07-12 | GSE200130 | GEO
2023-07-12 | GSE200131 | GEO